GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » Shares Buyback Ratio %

VYCO (Vycor Medical) Shares Buyback Ratio % : -2.28 (As of Dec. 13, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Vycor Medical Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Vycor Medical's current shares buyback ratio was -2.28%.

Vycor Medical Shares Buyback Ratio % Historical Data

The historical data trend for Vycor Medical's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vycor Medical Shares Buyback Ratio % Chart

Vycor Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.28 -8.47 -12.35 -5.54 -0.31

Vycor Medical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -2.28

Vycor Medical Shares Buyback Ratio % Calculation

Vycor Medical's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2022 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Dec. 2022 )
=(32.5272 - 32.6288) / 32.5272
=-0.31%

Vycor Medical's Shares Buyback Ratio for the quarter that ended in Sep. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2024 ) - Shares Outstanding (EOP) (A: Sep. 2024 )) / Shares Outstanding (EOP) (A: Jun. 2024 )
=(32.6288 - 33.3728) / 32.6288
=-2.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vycor Medical Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Vycor Medical's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vycor Medical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » Shares Buyback Ratio %
Comparable Companies
TNON VTAK INVO HSCS MOTS DYNT THMO AEMD NXL MHTX ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487
Website
https://www.vycormedical.com
Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.
Executives
David Cantor director, officer: President 1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000
Adrian Liddell director, officer: Chairman ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP
Peter C Zachariou director, 10 percent owner, officer: Chief Executive Officer C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014
Lowell Rush director C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Steven Girgenti director C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Fountainhead Capital Management Ltd 10 percent owner PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP

Vycor Medical Headlines

From GuruFocus

New Study Shows Vision Rehab Treatment Effective for Stroke and Injury Related Blindness

By Marketwired Marketwired • 02-27-2020

Treatment for blindness successful in largest ever study

By Marketwired Marketwired • 02-26-2020

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2017

By ACCESSWIRE AccessWire • 04-12-2019

Vycor Medical Reports Financial Results for the year ended December 31st, 2019

By Marketwired Marketwired • 03-27-2020

Vycor Value Could be Unlocked with These Major Partnerships

By Last Financier Last Financier • 12-05-2014

Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement

By Marketwired Marketwired • 06-30-2020

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2018

By ACCESSWIRE AccessWire • 04-12-2019